EICHOR
● Completed
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
Condition: Advanced Hepatocellular Carcinoma (HCC) · Sponsor: Shanghai Junshi Bioscience Co., Ltd.
About this study
This is a prospective, randomized, open-label, parallel-group, active controlled, multi-center phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab (hereafter referred to as JS001) combined with Bevacizumab versus Sorafenib as the first-line therapy for advanced HCC This study will enroll the patients with locally advanced or metastatic hepatocellular carcinoma who could not be radically cured and not receive any prior systemic therapy. The study will use PFS and OS as the co-primary endpoints, with approximately 280 patients planned to be enrolled.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (56)
| The First Affiliated Hospital of Bengbu Medical college | Bengbu, Anhui, China | — |
| Anhui Cancer Hospital | Hefei, Anhui, China | — |
| Anhui Provincial Hospital | Hefei, Anhui, China | — |
| The Second Hospital of Anhui Medical University | Hefei, Anhui, China | — |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | — |
| China PLA General Hospital | Beijing, Beijing Municipality, China | — |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | — |
| Army Medical Center of PLA | Chongqing, Chongqing Municipality, China | — |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | — |
| The Southwest Hospital Of AMU | Chongqing, Chongqing Municipality, China | — |
| The Frist Hospital of Lanzhou University | Lanzhou, Gansu, China | — |
| Gansu Wuwei Tumor Hospital | Wuwei, Gansu, China | — |
+ 44 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04723004